NOW APPROVED!
The Only FDA-Approved Dual Action Tablet for BRCA+ Metastatic Castration-Resistant Prostate Cancer (mCRPC)
AKEEGA™ (niraparib/abiraterone acetate) is the first and only FDA-approved dual action tablet combining PARP inhibition and novel hormone therapy that delivers precision medicine for BRCA+ mCRPC.
Janssen has built a legacy of innovation in the treatment of prostate cancer with the goal of extending life and helping patients enjoy the highest possible quality of life.